Nijholt, Kirsten T.
Sánchez-Aguilera, Pablo I.
Mahmoud, Belend
Gerding, Albert
Wolters, Justina C.
Wolters, Anouk H. G.
Giepmans, Ben N. G.
Silljé, Herman H. W.
de Boer, Rudolf A.
Bakker, Barbara M.
Westenbrink, B. Daan
Funding for this research was provided by:
ZonMw (91111.006)
Nederlandse Organisatie voor Wetenschappelijk Onderzoek (184.034.014, 016.176.147)
Hartstichting (2020-8005, 2019T064)
European Research Council (818715)
Article History
Received: 15 July 2023
Accepted: 26 October 2023
First Online: 1 November 2023
Competing interests
: The UMCG, which employs Nijholt, Sánchez-Aguilera, Mahmoud, Gerding, J.C. Wolters, A.H.G. Wolters, Giepmans, Silljé, de Boer, Bakker and Westenbrink, has received research grants and/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals Gmbh, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche. Dr. de Boer reports having received speaker fees from Abbott, AstraZeneca, Bayer, Novartis and Roche.